NASDAQ: LMDXLumiradx Ltd Stock
$0.26+0.00 (+0%)
Updated Sep 27, 2023
LMDX Price
$0.26
Fair Value Price
N/A
Market Cap
$82.91M
52 Week Low
$0.25
52 Week High
$1.61
P/E
-0.24x
P/B
0.39x
P/S
1.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$126.52M
Earnings
-$338.03M
Gross Margin
-4.3%
Operating Margin
-204.77%
Profit Margin
-267.2%
Debt to Equity
-0.42
Operating Cash Flow
-$130M
Beta
0.07
Next Earnings
Nov 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
LMDX Overview
LumiraDx Limited offers a platform that supports various tests with lab comparable performance at the point of care. The company has 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. LumiraDx was founded in 2014 and is headquartered in London, UK.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LMDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LMDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LMDX is good value based on its book value relative to its share price (0.39x), compared to the US Diagnostics & Research industry average (3.91x)
P/B vs Industry Valuation
LMDX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LMDX due diligence checks available for Premium users.
Be the first to know about important LMDX news, forecast changes, insider trades & much more!
LMDX News
Valuation
LMDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.24x
Industry
25.8x
Market
13.45x
LMDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
3.91x
LMDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LMDX's financial health
Profit margin
Revenue
$21.0M
Net Income
-$49.7M
Profit Margin
-236.8%
LMDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LMDX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$340.8M
Liabilities
-$89.0M
Debt to equity
-0.42
LMDX's short-term assets ($175.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LMDX's short-term assets ($175.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LMDX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LMDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.1M
Investing
-$821.0k
Financing
-$14.8M
LMDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LMDX vs Diagnostic & Research Stocks
Lumiradx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.